What can i really say; we are not really like any other biotechs for the most part even though we live in a premiere biotech area and collaborate with the very best minds we can find. Any number of our inventions can bring 10's to 100's of millions to billions depending on "proof". Proof is the key and you see us doing lots of experiments and reporting on the successes but we have our failures too like many companies - perhaps the difference is the volume of IP we hold - no one would buy it all but they could buy pieces now couldn't they - i mean thats the idea right - we off one piece of human proofed IP and we can self-fund everything. Many companies have one doo-dah and if it fails they are toast - what you see presented is everything that didn't fail thus far - we don't file patents on failed experiments and we don't file unless we think we can own the space. This is why there are so many stemvacs related patents. We have to own the space and we have to lay enough land mines that any invaders have to seek our permission to advance their cause which may need our IP.
Things that are coming out now are experiments and such that we commissioned a year ago and the list is long... so if pajama boi's are still crying let em cry more because we have lots of stuff coming down the pike you haven't even hard about yet... oh a week in the woods cleared the noggin and i'm ready to sizzle some brain cells.
TSOI_Ry wrote: ↑Wed Jun 02, 2021 11:39 am Then, maybe a better question is, which wealthy influential Pharmaceutical firm will seek to profit from groundbreaking cellular regeneration?? And how long will the line be? And who’s up first?
Biotech’s research and develop, Big Pharma acquires (via licensing/partnership/buy out etc), sells, distributes.
But first, proof. When the proof is empirical, the rest will undoubtedly fall into place. With efficacy rates of 91% (JadiCell/lung/Florida/2020 and 100% (StemVacs 1st Gen/2015-18/MX/Stage 4 cancer) I’d wager there are eyes on these coming ph3 FDA trials. But we aren’t RGBP. There’s no reason to cut quick low ball deals.
There in, I believe, is the difference. We’re positioned differently; smartly. Nearly 50 patents. Firing on all cylinders. Unfortunately, all we can do while we wait is speculate about how the market will react when the “big news” drops. But that’s really just the beginning. There’s still a well thought out road to be traveled ahead. Think EPS. We don’t control pps until then. And I’d add, what political animal would want his/her name aside a “cure for lung injury/ Covid-19 patients”. Or a “cure for Cancer”?
All in due time my friend. Your point is a good one, it’s a bit of a rigged game, but how many horse and buggy’s do you see on the road? Change is coming.